You are here: Industry Insights > Lung

News List

TFF Pharmaceuticals, Felix Biotechnology sign LOI for collaboration, development and licence agreement pharmaceutical-business-review
November 10, 2020
TFF Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, and Felix Biotechnology, a clinical stage ...
First Patient Dosed in Trial to Treat Complications in COVID-19 americanpharmaceuticalreview
October 22, 2020
Arch Biopartners has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to ...
BDR Pharma launches Nintenib (Nintedanib) to treat idiopathic pulmonary fibrosis in India expresspharma
October 21, 2020
BDR Pharma announced the launch of 100 mg and 150 mg Nintedanib under the brand name Nintenib for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Irisys Signs Contract with TFF Pharma contractpharma
October 10, 2020
Irisys LLC has announced its third contract for production and manufacturing in partnership with TFF Pharmaceuticals Inc.
Researchers to test potential COVID-19 treatment in UK pharmatimes
June 16, 2020
Researchers are gearing up to evaluate whether a new drug can prevent lung damage and blood clots in people with COVID-19 in hospitals in the UK.
Nobel Prize-Winning Scientist Explains Why New Study in New England Journal of Medicine May Point To Nitric Oxide as Successful Treatment For COVID-19 prnewswire
June 09, 2020
Although the recent study "Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19" by Ackermann, et al does not include any mention of nitric oxide, many of the world's leading researchers and scientists agree that ...
Study reveals distinct features of deceased COVID-19 patients’ lungs expresspharma
May 27, 2020
The researchers speculate that the greater degree of clot formation and blood vessel generation in COVID-19 patients may have contributed to the unique lung features.
Xylyx Bio Offers Advanced Lung Models to Accelerate COVID-19-Related Drug Development americanpharmaceuticalreview
April 16, 2020
Xylyx Bio announced availability of products that recreate the lung environment in vitro to provide a predictive model.
Theravance Responds to COVID-19 Pandemic contractpharma
April 14, 2020
Theravance Biopharma said that it is advancing TD-0903, a lung-selective nebulized Janus kinase inhibitor (JAKi) into clinical development.
Covid-19: MannKind, Pneumagen conduct research pharmaceutical-technology
March 19, 2020
MannKind has shifted the research and development (R&D) resources allotted for its lung diseases pipeline to help fight respiratory viral infections, including Covid-19.

Previous page 1 2 3 4 5 6 7 8 9 Next page